Press release
Migraine Market to Expand at a Significant Growth Rate During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - AbbVie, Axsome Therapeutics, Biohaven Pharma, Impel NeuroPharma, Satsuma Pharma, Tonix Pharma, Biohaven Pharma, Zosano P
DelveInsight's "Migraine Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Migraine Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Migraine market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Migraine: An Overview
Migraine, a primary headache disorder, is a neurological condition which causes multiple symptoms frequently characterized by intense, debilitating headaches. It often runs in families and affect all ages. It is of majorly two types: acute and chronic migraine.
The exact cause of migraine is unknown, but they are thought to be the result of abnormal brain activity temporarily affecting nerve signals, chemicals and blood vessels in the brain. Many possible migraine triggers have been suggested, including hormonal, emotional, physical, dietary, environmental and medicinal factors. These triggers vary among individuals, but a diary may help keep tracking of consistent
trigger.
According to a study, almost three billion individuals were estimated to have a migraine or tension-type headache in 2016 in which 1•89 billion population are with tension-type headache and 1•04 billion are with migraine.
Migraine Market Key Facts
• The market size of Migraines in the seven major markets was found to be USD 6,960.14 million in 2021.
• The total Migraine prevalent population in the 7MM was 118,491,327 cases in 2021.
• According to Rebecca et al. (2019), migraine is common, and occurs in about 12% of the US population overall, 18% of women, and 6% of men, each year.
• According to a study by Burch R. et al., (2018) stated that results from the National Health Interview Survey (NHIS) show that self-reported migraine and severe headache was reported by 15.3% of Americans overall, including 9.7% of men and 20.7% of women.
Migraine Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Migraine market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Migraine market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Discover How Migraine Market Will Grow by 2032:
https://www.delveinsight.com/report-store/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Migraine Epidemiology
The epidemiology section covers detailed insights into the historical and current Migraine patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.
The Report Covers the Migraine Epidemiology Segmented as -
• Total Prevalent Cases of Migraine in the 7MM [2019-2032]
• Prevalent Cases of Migraine by severity in the 7MM (Episodic and Chronic Migraine) [2019-2032]
• Gender-specific Prevalence of Migraine in the 7MM [2019-2032]
• Diagnosed Cases of Migraine in the 7MM [2019- 2032]
Get Key Insights Into the Evolving Migraine Epidemiology Trends:
https://www.delveinsight.com/report-store/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Migraine Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to be launched during the study period. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug.
The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Migraine Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Migraine Therapeutics Assessment
There are approx. 30+ key companies developing therapies for Migraines. Currently, Novartis is leading the therapeutics market with its Migraine drug candidates in the most advanced stage of clinical development.
The Leading Players in the Migraine Therapeutics Market Include:
• Satsuma Pharmaceuticals
• Biohaven Pharmaceuticals
• Allodynic Therapeutics
• Vaxxinity
• AbbVie
• Pulmatrix
• AEON Biopharma
• Eli Lilly and Company
• Trevena
• Xoc Pharmaceuticals
• Pharmaleads
• Pear Therapeutics
And Many Others
Migraine Emerging and Marketed Drugs Covered in the Report Include:
• Atogepant: AbbVie
• AXS-07: Axsome Therapeutics
• BHV-3500 (Zavegepant): Biohaven Pharmaceuticals
• INP104: Impel NeuroPharma
• STS-101: Satsuma Pharmaceuticals
• TNX1900: Tonix Pharmaceuticals
• Vyepti (eptinezumab): Lundbeck Seattle Biopharmaceutical
• Zavegepant: Biohaven Pharmaceuticals
• Zolmitriptan transdermal: Zosano Pharma
And Many More
Learn More About the Emerging Therapies & Key Companies in the Migraine Therapeutics Market:
https://www.delveinsight.com/sample-request/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Migraine Competitive Intelligence Analysis
4. Migraine Market Overview at a Glance
5. Migraine Background and Overview
6. Migraine Patient Journey
7. Migraine Epidemiology and Patient Population
8. Migraine Treatment Algorithm, Current Treatment, and Medical Practices
9. Migraine Unmet Needs
10. Key Endpoints of Migraine Treatment
11. Migraine Marketed Products
12. Migraine Emerging Therapies
13. Migraine Seven Major Market Analysis
14. Attribute Analysis
15. Migraine Market Outlook (7 major markets)
16. Migraine Access and Reimbursement Overview
17. KOL Views on the Migraine Market.
18. Migraine Market Drivers
19. Migraine Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Other Trending Healthcare Report by DelveInsight
- Acute Respiratory Distress Syndrome (ARDS) Market
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
- Biliary Tract Cancers (BTCs) Market
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
- Complicated Urinary Tract Infections Market
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
- Congenital Adrenal Hyperplasia Market
https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market
- Ulcerative Colitis (UC) Market
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market
- Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
- Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market
- Axial Spondyloarthritis Market
https://www.delveinsight.com/report-store/axial-spondyloarthritis-market
- Adult-onset Still Disease Market
https://www.delveinsight.com/report-store/adult-onset-still-disease-market
- Amebiasis Market
https://www.delveinsight.com/report-store/amebiasis-market
- Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market
- Antibody-mediated Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
- Candidemia Market
https://www.delveinsight.com/report-store/candidemia-market
- Cardiovascular Calcification Market
https://www.delveinsight.com/report-store/cardiovascular-calcification-market
Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine Market to Expand at a Significant Growth Rate During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - AbbVie, Axsome Therapeutics, Biohaven Pharma, Impel NeuroPharma, Satsuma Pharma, Tonix Pharma, Biohaven Pharma, Zosano P here
News-ID: 3029563 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Migraine
Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share?
The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market?
The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes.
Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR…
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market.
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive…
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which…
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases.
The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs.
Get Access to TOC /…
